FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)

View source ↗

Summary

The FDA approved a supplemental application for HICON (sodium iodide I-131) submitted by Jubilant DraxImage Inc., dba Jubilant Radiopharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Graves Disease
• Hyperthyroidism
• Toxic Multinodular Goiter

Drugs mentioned

• HICON (Sodium Iodide I-131)

Snippet

SUPPL AP for HICON (SODIUM IODIDE I 131)